This recommendation statement from the Second Panel on Cost-Effectiveness in Health and Medicine reviews methodological advances in cost-effective analyses and updates the 1996 recommendations for the conduct and report of cost-effective analyses.
This study compares health care costs and outcomes for patients with joint replacement or sepsis before and after implementation of a value-drive outcomes program designed to give physicians information about clinical outcomes, costs, and variation.
This study estimates the cost-effectiveness of adding proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to statin therapy for patients with heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascular disease (ASCVD).
This cohort study uses Healthcare Cost and Utilization Project data to compare mortality and health services use among patients hospitalized during an initial emergency department (ED) visit vs those discharged from the ED and hospitalized during a second unscheduled visit.
This systematic review analyzes how physicians are educated to deliver high-value, cost-conscious care and the circumstances that influence this learning.
This Viewpoint from the National Academy of Medicine’s 2016 Vital Directions initiative proposes health infrastructure and policy changes to improve care for high-need, high-cost patients.
This cohort study compares patient outcomes, health care utilization, and costs for patients receiving primary care in integrated team-based care (TBC) vs traditional practice management (TPM) practices (usual care).
This Special Communication summarizes published evidence about the causes of elevated prescription drug prices in the United States and proposes policy options to mitigate the effects of high prices while preserving incentives for development and innovation.
This study compares the cost-effectiveness of using various 10-year atherosclerotic cardiovascular disease risk thresholds for initiating statin therapy.